Trial Profile
Effects of Olmesartan and Azilsartan on biomarkers of progression of CKD and arteriosclerosis in CKD patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 23 Feb 2018
Price :
$35
*
At a glance
- Drugs Azilsartan (Primary) ; Olmesartan medoxomil (Primary)
- Indications Hypertension
- Focus Biomarker; Pharmacodynamics
- 22 Feb 2018 Status changed from not yet recruiting to discontinued.
- 04 Dec 2014 New trial record